FDA and EMA Hit Zhejiang Huahai Over GMP Violations

Drug Industry Daily
A A
The FDA placed valsartan manufacturer Zhejiang Huahai on an import alert Friday and the EMA issued a noncompliance statement barring Europe’s drugmakers from using the company’s API in their blood pressure products.

To View This Article:

Login

Subscribe To Drug Industry Daily